Phycocyanin liposomes for topical anti-inflammatory activity: In-vitro in-vivo studies

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 4, 2009, Pages 423-430

  Manconia, Maria ^a   Pendás, Jehzabel ^b,e   Ledón, Nurys ^c   Moreira, Tomás ^b   Sinico, Chiara ^a   Saso, Luciano ^d   Fadda, Anna Maria ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^c CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

Cutaneous delivery; Dehydrated Rehydrated vesicles; Inflammation; Liposomes; Phycocyanin

Indexed keywords

ARACHIDONIC ACID; CARBOMER; CHOLESTEROL; CROTON OIL; INDOMETACIN; LIPOSOME; PHOSPHATIDYLCHOLINE; PHYCOCYANIN; TRIAMCINOLONE; ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; EAR; EDEMA; ENCAPSULATION; FLUORESCENCE MICROSCOPY; GEL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LASER; LIGHT SCATTERING; MICROSCOPY; MORPHOLOGY; NONHUMAN; RAT; SKIN INFLAMMATION; SKIN PENETRATION; SKIN PERMEABILITY; STRATUM CORNEUM; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; CHEMICALLY INDUCED DISORDER; INTRADERMAL DRUG ADMINISTRATION; MALE; METABOLISM; METHODOLOGY; SKIN; SKIN ABSORPTION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; CROTON OIL; DRUG DELIVERY SYSTEMS; EAR; EDEMA; HUMANS; LIPOSOMES; MALE; PHYCOCYANIN; RATS; SKIN; SKIN ABSORPTION;

EID: 85047686272     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.04.0002     Document Type: Article

References (41)

1. Otles S, Pire R. Fatty acid composition of Chlorella and Spirulina microalgae species. J AOAC Int 2001; 84: 1708-1714.
2. Pugh N et al. Isolation of three weight polysaccharide preparations with potent immunostimulatory activity from Spirulina platensis, Aphanizomenon flos-aguae and Chlorella pyrenoidosa. Planta Med 2001; 67: 737-742.
3. Cohen Z. Products from microalgae. In: Richmond A, ed. Handbook of Microalgal Mass Culture. Boca Raton: CRC Press Inc, FL, 1986: 421-454.
4. Yoshida A et al. Enzyme immunoassay for phycocyanin as the main component of Spirulina color in foods. Biosci Biotechnol Biochem 1996; 60: 57-60.
5. Glazer AN. Phycobiliproteins - a family of valuable, widely used fluorophores. J Appl Phycol 1994; 6: 105-112.
6. Romay C et al. Antioxidant and anti-inflammatory properties of C-phycocyanin from blue-green algae. Inflamm Res 1998; 47: 36-41.
7. Romay C et al. C-phycocyanin: a biliprotein with antioxidant, anti-inflammatory and neuroprotective effects. Curr Protein Pept Sci 2003; 4: 207-216.
8. Bhat VB, Madyastha KM. C-phycocyanin: a potent peroxyl radical scavenger in vivo and in vitro. Biochem Biophys Res Commun 2000; 275: 20-25.
9. Benedetti S et al. Antioxidant properties of a novel phycocyanin extract from the blue-green alga Aphanizomenon flos-aquae. Life Sci 2004; 75: 2353-2362.
10. Romay C et al. Phycocyanin extract reduces leukotriene B4 levels in arachidonic acid-induced mouse-ear inflammation test. J Pharm Pharmacol 1999; 51: 641-642.
11. Reddy CM et al. Selective inhibition of cyclooxygenase-2 by C-phycocyanin, a biliprotein from Spirulina platensis. Biochem Bioph Res Commun 2000; 277: 599-603.
12. Cherng SC et al. Anti-inflammatory activity of c-phycocyanin in lipopolysaccharide-stimulated RAW 264.7 macrophages. Life Sci 2007; 81: 1431-1435.
13. Madhyastha HK et al. uPA dependent and independent mechanisms of wound healing by C-phycocyanin. J Cell Mol Med 2008; 12: 2691-2703.
14. Amsden BG, Goosen MFA. Transdermal delivery of peptide and protein drugs: an overview. AIChE J 1995; 41: 1972-1997.
15. Cross SE, Roberts MS. Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development? Curr Drug Deliv 2004; 1: 81-92.
16. Weiner N et al. Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model. Antimicrob Agents Chemother 1989; 33: 1217-1221.
17. Schereier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control. Release 1994; 30: 1-15.
18. Cevc G et al. Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim Biophys Acta 1998; 1368: 201-215.
19. Waranuch N et al. Controlled topical delivery of ciclosporyn A from nonionic liposomal formulations: mechanistic aspects. J Liposome Res 1998; 8: 225-238.
20. Foldvari M et al. Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon. Biotechnol Appl Biochem 1999; 30: 129-137.
21. Touitou E et al. Enhanced delivery of drugs into and across the skin by ethosomal carriers. Drug Dev Res 2000; 50: 406-415.
22. King MJ et al. Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther 2002; 4: 479-488.
23. Schuetz A et al. Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv 2005; 2: 533-548.
24. Kirby C, Gregoriadis G. Dehydration-rehydration vesicles (DRV): A new method for high yield drug entrapment in liposomes. Biotechnology 1984; 11: 979-984.
25. Baricevic D et al. Topical anti-inflammatory activity of Salvia officinalis L. leaves: the relevance of ursolic acid. J Ethnopharmacol 2001; 75: 125-132.
26. Ishii K et al. A useful method for differential evaluation of antiinflammatory effects due to cyclooxygenase and 5-lipoxygenase inhibitions in mice. Jpn J Pharmacol 1994; 65: 297-303.
27. Suzuki K et al. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem 1983; 132: 345-352.
28. De Young L et al. Edema and cell infiltration in the phorbol treated mouse ear are temporally separate and can be differentially modulate by pharmacological agents. Agents Actions 1989; 26: 335-341.
29. Cortesi R et al. Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity. Int J Pharm 2006; 317: 90-100.
30. Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control. Release 2006; 113: 9-14.
31. Ricci M et al. Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation. Int J Pharm 2006; 311: 172-181.
32. Sinico C et al. Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicleskin interaction. J Control. Release 2005; 103: 123-136.
33. Sinico C et al. Octyl/decyl polyglucoside niosomes as potential carriers for the cutaneous delivery of 8-methoxypsoralen. J Drug Deliv Sci Technol 2006; 311: 115-120.
34. Manconi M et al. Niosomes as carriers for tretinoin III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin. Int J Pharm 2006; 311: 11-19.
35. Mura S et al. Liposomes and niosomes as potential carriers for minoxidil. J Drug Targ 2007; 15: 101-108.
36. Bowstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Del Rev 2002; 54: S41-S55.
37. Crummey A et al. Inhibition of arachidonic acid-induced ear oedema as a model for assessing topical anti-inflammatory compounds. Inflamm Res 1987; 20: 69-76.
38. Tubaro A et al. The croton oil ear test revisited. Agents Actions 1986; 17: 347-349.
39. Fabia R et al. The role of transient mucosal ischemia in acetic acid-induce colitis in the rat. J Surg Res 1996; 63: 406-412.
40. Gonzalez R et al. Anti-inflammatory activity of phycocyanin extract in acid acetic-induced colitis in rats. Pharmacol Res 1999; 39: 55-59.
41. McConnico RS et al. Myeloperoxidase activity of the large intestine in an equine model of acute colitis. Am J Vet Res 1999; 60: 807-813.